For the quarter ending 2025-09-30, HCAT had -$10,407K decrease in cash & cash equivalents over the period. -$719K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -22,229 | -64,720 |
| Stock-based compensation expense | 7,039 | 15,866 |
| Depreciation and amortization | 12,614 | 25,004 |
| Impairment of long-lived assets | 6,900 | 0 |
| Non-cash operating lease expense | -747 | -1,484 |
| Amortization of debt discount, issuance costs, and deferred financing costs | 817 | 2,089 |
| Investment discount and premium accretion | 345 | 933 |
| Provision for expected credit losses | 300 | 1,110 |
| Deferred tax provision | 43 | -157 |
| Change in fair value of contingent consideration liability | -1,895 | -5,168 |
| Goodwill impairment | 0 | 28,769 |
| Other | 374 | -784 |
| Accounts receivable, net | -7,924 | 10,633 |
| Prepaid expenses and other assets | 534 | -2,468 |
| Accounts payable, accrued liabilities, and other liabilities | -3,091 | -12,638 |
| Deferred revenue | -8,119 | 11,423 |
| Operating lease liabilities | -1,009 | -1,897 |
| Net cash (used in) provided by operating activities | -464 | -8,717 |
| Proceeds from the sale and maturity of short-term investments | 6,240 | 143,208 |
| Purchase of short-term investments | 10,464 | 46,760 |
| Acquisition of businesses, net of cash acquired | 0 | 41,114 |
| Capitalization of internal-use software | 4,552 | 10,086 |
| Purchases of property and equipment | 255 | 440 |
| Purchase of intangible assets | 328 | 296 |
| Proceeds from the sale of property and equipment | 6 | 25 |
| Net cash provided by investing activities | -9,353 | 44,537 |
| Proceeds from issuance of long-term debt, net of issuance costs | 0 | - |
| Proceeds from employee stock purchase plan | 534 | 1,003 |
| Repurchase of common stock | 0 | 5,000 |
| Repayment of debt | 1,071 | 230,814 |
| Payment of deferred financing costs | 0 | - |
| Proceeds from exercise of stock options | 0 | 0 |
| Net cash (used in) provided by financing activities | -537 | -234,811 |
| Effect of exchange rate changes on cash and cash equivalents | -53 | 58 |
| Net (decrease) increase in cash and cash equivalents | -10,407 | -198,933 |
| Cash and cash equivalents at beginning of period | 249,645 | - |
| Cash and cash equivalents at end of period | 40,305 | - |
Health Catalyst, Inc. (HCAT)
Health Catalyst, Inc. (HCAT)